T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines
Not available.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-05-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12080 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850123727208972288 |
|---|---|
| author | Cilia R. Pothast Quincy Hofsink Sabine Haggenburg Romy C. Dijkland Marian van de Meent Kayleigh van Dijk Michel S. Bhoekhan Nienke J.E. Haverkate Johan van Meerloo J.H. Frederik Falkenburg Ruben A.L. de Groen Annoek E.C. Broers Jaap A. van Doesum Rob S. van Binnendijk Gerco den Hartog Birgit I. Lissenberg-Witte Arnon P. Kater Gaby P. Smits Dorine Wouters Ester M.M. van Leeuwen Hetty J. Bontkes Neeltje A. Kootstra Sandra Vogels-Nooijen Debbie van Baarle Rory D. de Vries Tom van Meerten Pim G.N.J. Mutsaers Abraham Goorhuis Inger S. Nijhof Mette D. Hazenberg Mirjam H.M. Heemskerk Caroline E. Rutten COBRA KAI study team |
| author_facet | Cilia R. Pothast Quincy Hofsink Sabine Haggenburg Romy C. Dijkland Marian van de Meent Kayleigh van Dijk Michel S. Bhoekhan Nienke J.E. Haverkate Johan van Meerloo J.H. Frederik Falkenburg Ruben A.L. de Groen Annoek E.C. Broers Jaap A. van Doesum Rob S. van Binnendijk Gerco den Hartog Birgit I. Lissenberg-Witte Arnon P. Kater Gaby P. Smits Dorine Wouters Ester M.M. van Leeuwen Hetty J. Bontkes Neeltje A. Kootstra Sandra Vogels-Nooijen Debbie van Baarle Rory D. de Vries Tom van Meerten Pim G.N.J. Mutsaers Abraham Goorhuis Inger S. Nijhof Mette D. Hazenberg Mirjam H.M. Heemskerk Caroline E. Rutten COBRA KAI study team |
| author_sort | Cilia R. Pothast |
| collection | DOAJ |
| description |
Not available.
|
| format | Article |
| id | doaj-art-d2fcf7bb6f3d4cee942ec5bf78da20f2 |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-d2fcf7bb6f3d4cee942ec5bf78da20f22025-08-20T02:34:32ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-05-01999110.3324/haematol.2024.287136T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccinesCilia R. Pothast0Quincy Hofsink1Sabine Haggenburg2Romy C. Dijkland3Marian van de Meent4Kayleigh van Dijk5Michel S. Bhoekhan6Nienke J.E. Haverkate7Johan van Meerloo8J.H. Frederik Falkenburg9Ruben A.L. de Groen10Annoek E.C. Broers11Jaap A. van Doesum12Rob S. van Binnendijk13Gerco den Hartog14Birgit I. Lissenberg-Witte15Arnon P. Kater16Gaby P. Smits17Dorine Wouters18Ester M.M. van Leeuwen19Hetty J. Bontkes20Neeltje A. Kootstra21Sandra Vogels-Nooijen22Debbie van Baarle23Rory D. de Vries24Tom van Meerten25Pim G.N.J. Mutsaers26Abraham Goorhuis27Inger S. Nijhof28Mette D. Hazenberg29Mirjam H.M. Heemskerk30Caroline E. Rutten31COBRA KAI study team32Department of Hematology, Leiden UMC, LeidenDepartment of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, AmsterdamDepartment of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, AmsterdamDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, AmsterdamAmsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, AmsterdamDepartment of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, AmsterdamDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Erasmus MC Cancer Institute, RotterdamDepartment of Hematology, University Medical Center Groningen, University of Groningen, GroningenCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Laboratory of Medical Immunology, Department of Laboratory Medicine, Radboudumc, NijmegenCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, BilthovenDepartment of Epidemiology and Data Science, Amsterdam UMC location Vrije Universiteit, AmsterdamDepartment of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, AmsterdamCentre for Immunology of Infectious Diseases and Vaccines, National Institute for Public Health and the Environment, BilthovenDepartment of Laboratory Medicine, Central Diagnostic Laboratory, Amsterdam UMC, AmsterdamAmsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Department of Laboratory Medicine, Laboratory for Specialized Diagnostics and Research, Laboratory Medical Immunology, Amsterdam UMC, AmsterdamAmsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Laboratory Medicine, Laboratory for Specialized Diagnostics and Research, Laboratory Medical Immunology, Amsterdam UMC, AmsterdamAmsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Department of Experimental Immunology, Amsterdam UMC location University of Amsterdam, AmsterdamNetherlands Comprehensive Cancer Organisation, UtrechtDepartment of Medical Microbiology and Infection Prevention, University Medical Center Groningen, GroningenDepartment of Viroscience, Erasmus University Medical Center, RotterdamDepartment of Hematology, University Medical Center Groningen, University of Groningen, GroningenDepartment of Hematology, Erasmus MC Cancer Institute, RotterdamDepartment of Infectious Diseases, Amsterdam UMC location University of Amsterdam, AmsterdamDepartment of Hematology, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Internal Medicine-Hematology, St. Antonius Hospital, NieuwegeinDepartment of Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Institute for Infection and Immunity, Amsterdam UMC, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands; Department of Hematopoiesis, Sanquin Research, AmsterdamDepartment of Hematology, Leiden UMC, LeidenDepartment of Hematology, Amsterdam UMC location University of Amsterdam, AmsterdamIris Kant, Thecla Graas, Belle Toussaint, Sterre de Jong, Shahan Darwesh, Sandjiv Mahes, Dora Kamminga, Matthijs Koelewijn, Gino Faber, Guus Beaumont, Marije Engel, R. Cheyenne Pierie, Suzanne Janssen, Kazimierz Groen, Judith Burger, Joey Bouhuijs, Paul Baars, Marit van Gils, Edith van Dijkman, Jarom Heijmans, Yara Witte, Rogers Nahui Palomino, Said Omar, Sonja Zweegman, Caya van den Vegt, Ilonka Arends-Halbesma, Emma de Pater, Margriet Dijkstra, Nynke Rots, Esther Siteur-van Rijnstra, Dennis de Rooij, Rogier Sanders, Meliawati Poniman, Wouter Olijhoek, Jacqueline van Rijswijk, Tim Beaumont, Lusia Çetinel, Louis Schellekens, Yvonne den Hartogh, Jacqueline Cloos, Suzanne Weijers, Saïda Tonouh-Aajoud, Selime Avci, Elianne Roelandse-Koop, Willem Dik Not available. https://haematologica.org/article/view/12080 |
| spellingShingle | Cilia R. Pothast Quincy Hofsink Sabine Haggenburg Romy C. Dijkland Marian van de Meent Kayleigh van Dijk Michel S. Bhoekhan Nienke J.E. Haverkate Johan van Meerloo J.H. Frederik Falkenburg Ruben A.L. de Groen Annoek E.C. Broers Jaap A. van Doesum Rob S. van Binnendijk Gerco den Hartog Birgit I. Lissenberg-Witte Arnon P. Kater Gaby P. Smits Dorine Wouters Ester M.M. van Leeuwen Hetty J. Bontkes Neeltje A. Kootstra Sandra Vogels-Nooijen Debbie van Baarle Rory D. de Vries Tom van Meerten Pim G.N.J. Mutsaers Abraham Goorhuis Inger S. Nijhof Mette D. Hazenberg Mirjam H.M. Heemskerk Caroline E. Rutten COBRA KAI study team T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines Haematologica |
| title | T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines |
| title_full | T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines |
| title_fullStr | T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines |
| title_full_unstemmed | T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines |
| title_short | T-cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of SARS-CoV-2 mRNA vaccines |
| title_sort | t cell and antibody responses in immunocompromised patients with hematologic malignancies indicate strong potential of sars cov 2 mrna vaccines |
| url | https://haematologica.org/article/view/12080 |
| work_keys_str_mv | AT ciliarpothast tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT quincyhofsink tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT sabinehaggenburg tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT romycdijkland tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT marianvandemeent tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT kayleighvandijk tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT michelsbhoekhan tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT nienkejehaverkate tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT johanvanmeerloo tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT jhfrederikfalkenburg tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT rubenaldegroen tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT annoekecbroers tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT jaapavandoesum tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT robsvanbinnendijk tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT gercodenhartog tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT birgitilissenbergwitte tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT arnonpkater tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT gabypsmits tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT dorinewouters tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT estermmvanleeuwen tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT hettyjbontkes tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT neeltjeakootstra tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT sandravogelsnooijen tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT debbievanbaarle tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT roryddevries tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT tomvanmeerten tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT pimgnjmutsaers tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT abrahamgoorhuis tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT ingersnijhof tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT mettedhazenberg tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT mirjamhmheemskerk tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT carolineerutten tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines AT cobrakaistudyteam tcellandantibodyresponsesinimmunocompromisedpatientswithhematologicmalignanciesindicatestrongpotentialofsarscov2mrnavaccines |